Genitourinary Cancer News

Editor’s note: This is the first in a series of five stories from ASCO Voices, a session during ASCO Annual Meeting focused on the human side of oncology.

In this video, Nour Abdallah, MD, discusses an abstract she presented at American Urological Association Annual Meeting, about artificial intelligence generation of the RENAL nephrometry score in the treatment of kidney cancer.

CHICAGO — In patients with metastatic non-clear cell renal cell carcinoma, a high systemic inflammatory state at baseline was associated with worse outcomes after treatment with atezolizumab and bevacizumab, according to a poster presented at ASCO Annual Meeting.

CHICAGO — Early cessation of chemotherapy as a result of intolerance had significant implications on pathologic response, OS and RFS in patients with muscle-invasive bladder cancer, according to a poster presentation at ASCO Annual Meeting.

ASCO Chief Medical Officer Julie R. Gralow, MD, FACP, FASCO, urged members of Congress to take action on cancer drug shortages, which she described as the worst she has witnessed during her 30-year career in oncology.

In this video, Nour Abdallah, MD, discusses an abstract examining the artificial intelligence-generated Centrality Index score presented at American Urological Association Annual Meeting.

CHICAGO — Healio | HemOnc Today gathered the best, brightest and boldest in oncology for its second annual Disruptive Innovators Awards.

CHICAGO — Pembrolizumab plus axitinib continued to confer a survival benefit vs. sunitinib at 5-year follow-up as first-line therapy for patients with advanced clear cell renal cell carcinoma, according to study results.

The FDA announced several regulatory actions the past few weeks.

CHICAGO — The addition of CBM588 to immune checkpoint inhibitor-based therapy significantly increased PFS and response rates with no impact on stool microbiome diversity among a small cohort of patients with metastatic renal cell carcinoma.